Drug Trial Radar · NCT01709149
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 20, 2026Latest source record: Mar 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
711
Actual
Start
Oct 2012
Primary completion
Mar 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- CytokineticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
CK-2017357Drug
CK-2017357 125 mg tablets twice daily
Placebo tabletsOther
Tablets
RiluzoleDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind TreatmentTime frame: Baseline, 8 weeks, 12 weeks
Locations
75 sites in 8 countries. Site status is shown where the registry gives one.
Barrow Neurology
Phoenix, Arizona
University of California, San Diego
La Jolla, California
UC Irvine ALS & Neuromuscular Center
Orange, California
Coordinated Clinical Research
San Diego, California
California Pacific Medical Center Forbes Norris MDA/ALS Research Center
San Francisco, California
Hospital for Special Care
New Britain, Connecticut
The George Washington University
Washington D.C., District of Columbia
Mayo Clinic Florida Department of Neurology
Jacksonville, Florida
Emory University, School of Medicine
Atlanta, Georgia
Georgia Health Sciences University
Augusta, Georgia
Indiana University Department of Neurology
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas
Kansas City, Kansas
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Massachusetts Medical School
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
St Mary's Healthcare
Grand Rapids, Michigan
Hennepin County Medical Center - Berman Center for Research
Minneapolis, Minnesota
Saint Louis University
St Louis, Missouri
Washington University
St Louis, Missouri
Neurology Associates
Lincoln, Nebraska
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Hospital for Special Surgery
New York, New York
University of Rochester
Rochester, New York
SUNY Upstate Medical University
Syracuse, New York
Carolinas Medical Center Department of Neurology
Charlotte, North Carolina
Duke University
Durham, North Carolina
Wake Forest University, School of Medicine
Winston-Salem, North Carolina
Ohio State University Department of Neurology
Columbus, Ohio
Providence ALS Center
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Penn State Hershey Neuroscience Clinics
Hershey, Pennsylvania
Drexel Neurology
Philadelphia, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Neurology
Dallas, Texas
Baylor College of Medicine
Houston, Texas
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.